I6A-MC-CBBA - ClinicalTrials.gov - NCT01655225
I6A-MC-CBBA - ClinicalTrials.gov - NCT01655225
Key Requirements
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Participants must
Participant in Part B4 must have malignant pleural or peritoneal mesothelioma and appropriate candidate for treatment with cisplatin/pemetrexed; no prior systemic chemotherapy
Participant in Part B6 must have squamous NSCLC; documented evidence of an activating molecular aberration of the PI3K/mTOR pathway
Participant in Part B7 must have HR+ abd HER2- breast cancer
Participant may need to undergo a biopsy dependent upon which arm of the study you are in
Participant must be able to swallow capsules
Participant must be reliable and willing to make themselves available for the duration of the study and be willing to follow study procedures
Participants must NOT
Participant must not have known acute or chronic leukemia
Participant must not have insulin-dependent diabetes mellitus or a history of gestational diabetes mellitus
Trial Summary
Conditions the trial is for
Advanced Cancer, Mesothelioma, Metastatic Breast Cancer, Non-small Cell Lung Cancer, Non-Hodgkin's Lymphoma
What the trial is testing?
LY3023414, Midazolam, Fulvestrant, Pemetrexed, Cisplatin, Abemaciclib, Letrozole
Could I receive a Placebo?
no
Enrollment Goal
164
Trial Dates
July 2012 - March 2021
Trial Phase
1
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Participants must
Participant in Part B4 must have malignant pleural or peritoneal mesothelioma and appropriate candidate for treatment with cisplatin/pemetrexed; no prior systemic chemotherapy
Participant in Part B6 must have squamous NSCLC; documented evidence of an activating molecular aberration of the PI3K/mTOR pathway
Participant in Part B7 must have HR+ abd HER2- breast cancer
Participant may need to undergo a biopsy dependent upon which arm of the study you are in
Participant must be able to swallow capsules
Participant must be reliable and willing to make themselves available for the duration of the study and be willing to follow study procedures
Participants must NOT
Participant must not have known acute or chronic leukemia
Participant must not have insulin-dependent diabetes mellitus or a history of gestational diabetes mellitus
Trial Summary
Conditions the trial is for
Advanced Cancer, Mesothelioma, Metastatic Breast Cancer, Non-small Cell Lung Cancer, Non-Hodgkin's Lymphoma
What the trial is testing?
LY3023414, Midazolam, Fulvestrant, Pemetrexed, Cisplatin, Abemaciclib, Letrozole
Could I receive a Placebo?
no
Enrollment Goal
164
Trial Dates
July 2012 - March 2021
Trial Phase
1
Trial Locations
Hide locations not currently recruiting